Global Erythropoietin Drugs Market Size & Outlook

The erythropoietin drugs industry worldwide is expected to reach a projected revenue of US$ 7,132.9 million by 2030. A compound annual growth rate of 1.7% is expected of the worldwide erythropoietin drugs industry from 2024 to 2030.
Revenue, 2023 (US$M)
$7,005.4
Forecast, 2030 (US$M)
$7,789.2
CAGR, 2024 - 2030
1.5%
Report Coverage
Worldwide

Global erythropoietin drugs market highlights

  • The global erythropoietin drugs market generated a revenue of USD 7,005.4 million in 2023 and is expected to reach USD 7,789.2 million by 2030.
  • The market is expected to grow at a CAGR (2024 - 2030) of 1.5% by 2030.
  • In terms of segment, biologics accounted for a revenue of USD 3,739.2 million in 2023.
  • Biosimilars is the most lucrative type segment registering the fastest growth during the forecast period.
  • In terms of region, North America was the largest revenue generating market in 2023.
  • Country-wise, U.S. is expected to register the highest CAGR from 2024 to 2030.

Global data book summary

Market revenue in 2023USD 7,005.4 million
Market revenue in 2030USD 7,789.2 million
Growth rate1.5% (CAGR from 2023 to 2030)
Largest segmentBiologics
Fastest growing segmentBiosimilars
Historical data covered2018 - 2022
Base year for estimation2023
Forecast period covered2024 - 2030
Quantitative unitsRevenue in USD million
Market segmentationBiologics, Biosimilars

Other key industry trends

  • In terms of revenue, the North America accounted for 40.0% of the global erythropoietin drugs market in 2023.
  • By country, the U.S. is projected to lead the global market in terms of revenue in 2030.
  • By country, U.S. is the fastest growing regional market and is projected to reach USD 2,566.4 million by 2030.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Erythropoietin Drugs Market Companies

Name Profile # Employees HQ Website

Global erythropoietin drugs market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to erythropoietin drugs market will help companies and investors design strategic landscapes.


Biologics was the largest segment with a revenue share of 53.38% in 2023. Horizon Databook has segmented the Global erythropoietin drugs market based on biologics, biosimilars covering the revenue growth of each sub-segment from 2018 to 2030.


  • Global Erythropoietin Drugs Type Outlook (Revenue, USD Million, 2018-2030)
    • Biologics
    • Biosimilars
  • Global Erythropoietin Drugs Product Outlook (Revenue, USD Million, 2018-2030)
    • Erythropoietin
    • Darbepoetin-alfa
  • Global Erythropoietin Drugs Application Outlook (Revenue, USD Million, 2018-2030)
    • Cancer
    • Renal Diseases
    • Neurology
    • Other Applications

Reasons to subscribe to Global erythropoietin drugs market databook:

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of Global erythropoietin drugs market databook

  • Our clientele includes a mix of erythropoietin drugs market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of global-level data and insights on the Global erythropoietin drugs market , including forecasts for subscribers. This global databook contains high-level insights into Global erythropoietin drugs market from 2018 to 2030, including revenue numbers, major trends, and company profiles.

Partial client list

  • logo

Global erythropoietin drugs market size, by regions, 2018-2030 (US$M)

Top 10 countries: Erythropoietin drugs market size, 2023 (US$M)

Global erythropoietin drugs market share, by type, 2023 & 2030 (%, US$M)

Erythropoietin drugs market: Opportunity assessment by country

Global erythropoietin drugs market, by region, 2023 (US$M)

Global erythropoietin drugs market size, by regions, 2018-2030 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more